X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This is a value-inflection acquisition for Sorrento as it brings in multiple NCE drug product candidates, including the previously licensed Abivertinib as an anchoring small molecule drug product for treating many different cancers and autoimmune diseases.
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: STI-5656
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 02, 2021
Details:
The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules, which potentially have applications for numerous human disease indications.
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: STI-5656
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: $450.0 million Upfront Cash: Undisclosed
Deal Type: Merger April 05, 2021
Details:
Sorrento gets an exclusive license to ACEA’s Abivertinib, a novel small molecule tyrosine kinase inhibitor that selectively targets both mutant forms of the epidermal growth factor receptor and Bruton’s tyrosine kinase, across all indications for all territories outside China.
Lead Product(s): Abivertinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sorrento Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
